Hypertrophic cardiomyopathy: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• SGLT2 2
• GLP-1 0
• MEK 2
• MAPK 0
• PI3K 0
• STAT3 0
• TTR 0
• AKT 0
• CTNNB1 0
• ERK 0
• IL-6 0
• KRAS 0
• mTOR 0
• NRF2 0
• PSEN1 0
• SHP2 0
• TP53 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NHLBI · U24

  2/2 Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy

  New England Research Institutes, Inc.· Wilmington, United States· US$806,069 awarded in fiscal year 2026· until Aug 2032

• NIH NHLBI · UG3

  1/2 Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy

  Icahn School of Medicine at Mount Sinai· New York, United States· US$946,567 awarded in fiscal year 2026· until Aug 2027

• NIH NHLBI · R01

  Discovery of modifier genes and molecular mechanisms in arrhythmogenic cardiomyopathy

  University of Tennessee Health Sci Ctr· Memphis, United States· US$769,447 awarded in fiscal year 2026· until May 2030

• NIH NHLBI · R01

  Mutation-specific responses to myosin inhibitors in human iPSC models of HCM

  University of Wisconsin-Madison· Madison, United States· US$581,307 awarded in fiscal year 2026· until May 2030

• NIH NHLBI · K99

  Investigating the interplay between viscoelastic and growth factor sequestering cues in iPSC-CMs

  University of California Santa Barbara· Santa Barbara, United States· US$130,955 awarded in fiscal year 2026· until Jul 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Bioinspired Modulation of Cardiac Troponin I Splicing to Treat Diastolic Dysfunction (TROPOSplice)

  Centro Nacional de Investigaciones Cardiovasculares Carlos Iii (F.s.p.)· Madrid, Spain· EU contribution €1,499,625· until Jan 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Pushing boundaries: Innovating ultrafast ultrasound imaging to explore genotype-phenotype interplay in young hypertrophic cardiomyopathy – Real-time diagnosis and personalized management (5D ULTRAFAST-HCM)

  Chu Hopitaux de Bordeaux· Talence, France· EU contribution €1,499,425· until Dec 2030

• European Commission (Horizon Europe) · HORIZON-ERC

  Boosting predictive concepts on arrhythmogenesis resolving and unifying cardiac electrophysiology and structural remodelling at organ-level (HeartCORE)

  Consiglio Nazionale Delle Ricerche· Roma, Italy· EU contribution €2,646,938· until Aug 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  INnovative risk Stratification of heart faIlure throuGH explainable machine learning and compuTational modeling of Left Ventricle (INSIGHT-LV)

  Politecnico di Milano· Milano, Italy· EU contribution €193,643· until May 2027

• European Commission (Horizon Europe) · HORIZON-RIA

  Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients using Hybrid Digital Twin Solutions (SMASH-HCM)

  Tampereen Korkeakoulusaatio Sr· Tampere, Finland· EU contribution €8,546,366· until Dec 2027· 9 countries

10 of 125 running projects, newest first. Listed amounts together: US$69.9m + €14.4m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Organoids 1
• Mendelian Randomization Analysis 8
• CRISPR-Cas Systems 2
• Gene Expression Profiling 17
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 8
• Proteomics 6
• Metabolomics 2
• Immunohistochemistry 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 39
• Machine Learning 14
• Deep Learning 8
• Cohort Studies 26
• Genome-Wide Association Study 9

• Genetically predicted lower FLT3L levels increase the risk of hypertrophic cardiomyopathy partly mediated by phosphate: Evidence from a 2-step Mendelian randomization analysis.

  Medicine (Baltimore), Jun 2026

• Antibody-mediated immune responses and cardiovascular disease: a Mendelian randomization study.

  Exp Biol Med (Maywood), May 2026

• Inhibition of adenosine kinase alleviates hypertrophic cardiomyopathy by ameliorating coronary microvascular dysfunction.

  ESC Heart Fail, May 2026

• Genetic insights into radiomic and proteomic changes under β1-blockers treatment in hypertensive heart disease and hypertrophic cardiomyopathy.

  BMC Med, Feb 2026

• Systolic and diastolic blood pressure, abdominal obesity, and alcohol consumption contribute to the risk of hypertrophic and dilated cardiomyopathies in European and East Asian populations.

  BMC Med, Dec 2025

• Polygenic prediction of cardiorespiratory fitness in the Trøndelag health study (HUNT).

  Sci Rep, Dec 2025

• The Utility of Genome-Wide Association Studies in Inherited Arrhythmias and Cardiomyopathies.

  Genes (Basel), Dec 2025

• Explore the relationships between gut microbiota and cardiomyopathies with the potential mediating effect of cytokines: A univariable and multivariable Mendelian randomization study.

  Medicine (Baltimore), Nov 2025

• Causal association of metformin treatment with diverse cardiovascular diseases: a Mendelian randomization analysis.

  Aging (Albany NY), Apr 2024

See which targets of this disease your abstract mentions, and go to the people working on them.